Disease · HP_0031273
Shock
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Shock. Diseases, record HP_0031273. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0031273
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Shock
- Open Targets ID
- HP_0031273
- Highest stage of its drugs
- Approval, for 2 of its 36 drugs, from EMA Human Drugs
Source Open Targets
Drugs36
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ANGIOTENSIN II | CHEMBL408403 | Protein | Approval | EMA Human Drugs | 1 | 0 | 0 | Drugs and targets |
| ANGIOTENSIN-II | CHEMBL2392353 | Protein | Approval | EMA Human Drugs | 1 | 0 | 0 | Drugs and targets |
| NOREPINEPHRINE | CHEMBL1437 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 3 | Drugs and targets |
| CENTHAQUINE | CHEMBL4594437 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 3 | 3 | Drugs and targets |
| SODIUM CHLORIDE | CHEMBL1200574 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| BLOOD, WHOLE | CHEMBL2108414 | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets | |
| DOBUTAMINE | CHEMBL926 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| TRANEXAMIC ACID | CHEMBL877 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| DOPAMINE | CHEMBL59 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EMPAGLIFLOZIN | CHEMBL2107830 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 36
See all 36 drugsTargets42
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRB1 | Adrenergic receptor | 4 | Adrenergic receptor agonist; Beta-1 adrenergic receptor agonist | Phase 3 | https://conductscience.org/library/genes/153 | Drugs and targets |
| ADRA1A | Adrenergic receptor | 3 | Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist | Phase 3 | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1B | Adrenergic receptor | 3 | Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist | Phase 3 | https://conductscience.org/library/genes/147 | Drugs and targets |
| ADRA1D | Adrenergic receptor | 3 | Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist | Phase 3 | https://conductscience.org/library/genes/146 | Drugs and targets |
| ADRB2 | Adrenergic receptor | 3 | Adrenergic receptor agonist; Beta-2 adrenergic receptor agonist | Phase 3 | https://conductscience.org/library/genes/154 | Drugs and targets |
| IFNAR1 | Interferon alpha/beta receptor | 3 | Interferon alpha/beta receptor agonist | Investigational new drug | https://conductscience.org/library/genes/3454 | Drugs and targets |
| IFNAR2 | Interferon alpha/beta receptor | 3 | Interferon alpha/beta receptor agonist | Investigational new drug | https://conductscience.org/library/genes/3455 | Drugs and targets |
| ADRA2A | Adrenergic receptor | 2 | Adrenergic receptor agonist | Phase 3 | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor | 2 | Adrenergic receptor agonist | Phase 3 | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor | 2 | Adrenergic receptor agonist | Phase 3 | https://conductscience.org/library/genes/152 | Drugs and targets |
1 to 10 of 42
See all 42 targetsTrials27
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01411852 | Field Trial of Hypotensive Versus Standard Resuscitation for Hemorrhagic Shock After Trauma | Phase 2 | 192 | 2014-10-20 | Blunt Trauma, Penetrating Wound, Hemorrhagic Shock | SODIUM CHLORIDE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03477006 | Pragmatic Prehospital Group O Whole Blood Early Resuscitation Trial | Phase 3 | 86 | 2021-10-06 | Hemorrhagic Shock | BLOOD, WHOLE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00676585 | Corticosteroid Therapy in Refractory Shock Following Cardiac Arrest | Phase 1/2 | 50 | 2017-05-17 | Cardiac Arrest | HYDROCORTISONE | Its record names the disease | ClinicalTrials.gov |
| NCT00973102 | Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen-Traumatic Hemorrhagic Shock (RESCUE - Shock) | Phase 2 | 50 | 2020-03-19 | Hemorrhagic Shock | ESTROGENS, CONJUGATED | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00314704 | Dopamine and Norepinephrine in Shock Patients | Phase 3 | 1,679 | Shock | DOPAMINE, NOREPINEPHRINE | Its record names the disease | ClinicalTrials.gov | |
| NCT04684719 | Type O Whole Blood and Assessment of Age During Prehospital Resuscitation Trial | Phase 3 | 1,020 | Hemorrhagic Shock, Traumatic Injury | BLOOD, WHOLE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT06070350 | Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children | Phase 3 | 1,000 | Hemorrhagic Shock, Trauma Injury | TRANEXAMIC ACID | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT05251181 | A Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent | Phase 3 | 430 | Hypovolemic Shock | CENTHAQUINE, SODIUM CHLORIDE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT05931601 | Early Initiated Vasopressor Therapy in the Emergency Department | Phase 3 | 320 | Shock, Shock, Septic, Hypotension, Hypotension and Shock, Hypotension Symptomatic, Hypovolemia, Hypovolemic Shock, Hypovolemic | NOREPINEPHRINE | Its record names the disease | ClinicalTrials.gov | |
| NCT04728932 | LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients | Phase 3 | 206 | Cardiogenic Shock, Extracorporeal Membrane Oxygenation Complication | LEVOSIMENDAN | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 27
See all 27 trialsComparisons in its trials16
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Standard Resuscitation (SR) vs Controlled Resuscitation (CR): Number of Ineligible Patients Enrolled at the Time of Randomization | 24 of 95 | 9 of 97 | 192 | NCT01411852 | Trial comparisons |
| Standard Resuscitation (SR) vs Controlled Resuscitation (CR): Hemorrhage Control Procedure Within 2 Hours of ED Arrival | 19 of 95 | 29 of 96 | 191 | NCT01411852 | Trial comparisons |
| Standard Resuscitation (SR) vs Controlled Resuscitation (CR): serious adverse events | 8 of 95 | 18 of 96 | 191 | NCT01411852 | Trial comparisons |
| Standard Resuscitation (SR) vs Controlled Resuscitation (CR): In-hospital Mortality | 15 of 91 | 8 of 95 | 186 | NCT01411852 | Trial comparisons |
| LTLR-WB vs Standard Care: Incidence of Multiple Organ Failure | 4 of 40 | 9 of 46 | 86 | NCT03477006 | Trial comparisons |
| LTLR-WB vs Standard Care: 28 Day All Cause Mortality | 10 of 40 | 12 of 46 | 86 | NCT03477006 | Trial comparisons |
| LTLR-WB vs Standard Care: 24 Hour Mortality | 6 of 40 | 8 of 46 | 86 | NCT03477006 | Trial comparisons |
| LTLR-WB vs Standard Care: deaths from any cause | 10 of 40 | 12 of 46 | 86 | NCT03477006 | Trial comparisons |
| LTLR-WB vs Standard Care: serious adverse events | 7 of 40 | 11 of 46 | 86 | NCT03477006 | Trial comparisons |
| Standard Resuscitation (SR) vs Controlled Resuscitation (CR): Acute Renal Failure Classification Score of Risk Without Glomerular Filtration Rate (GFR) | 3 of 24 | 11 of 35 | 59 | NCT01411852 | Trial comparisons |
1 to 10 of 16
See all 16 comparisons in its trialsPapers from its trials18
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0031273
GET https://conductscience.org/api/diseases/v1/HP_0031273/drugs?page=2